TGFB1 and idiopathic pulmonary fibrosis: Pirfenidone is a FDA/EMA approved drug for treating IPF (14) that inhibits TGFβ1 induced expression of Collagen type I and Heat Shock Protein 47 (HSP47) in human lung adenocarcinoma cells (15) and was recently shown to suppress proliferation in human pancreatic cancer cells (16) or inhibit motility of NSCLC cells by interfering with the urokinase system (17).